Sabinsa Curcumin C3 Reduct Approved by EFSA
Sabinsa President of European Operations, Dr. Umar Jan made statements about Curcumin C3 Reduct features and Novel Foods (New Product) Approval from EFSA for this product.
Dr. Umar Jan “It’s true that wider recognition of the health benefits of curcumin and
of the turmeric spice it’s sourced from has led to a huge growth in the supply of this ingredient.
But with brand-owners and consumers now more aware than ever of the question of bioavailability, our Curcumin C3 Reduct product stands out.
Ours is the only concentrated and enhanced ingredient of its type, where the curcuminoids
are already converted to Tetrahydrocurcuminoids (THCs).
This product contains pharmacologically active metabolites of curcuminoids. It can
swing into action inside the cells immediately – and provide measurable health benefits.
The fact that THCs are colourless or white, in contrast to brightlycoloured curcumin, also provides an advantage for formulators.”
Since we are on the topic of product formulation, there are other ways in which THCs offer greater versatility than alternative curcumin products. For example, THCs have demonstrated higher stability over a wide pH range than curcumin itself, demethoxycurcumin or bisdemethoxycurcumin – all of them significant components of turmeric.
Additionally, THCs are pharmacologically active metabolites of curcuminoids, and most of the health benefits of curcuminoids are attributed to the presence of these reductive
metabolites – here in the form of C3 Reduct.
Specifically, C3 Reduct has been shown in several studies to outperform curcumin on pharmacological activity. Other curcumin metabolites such as curcumin glucuronide
and curcumin sulphate are biologically inactive.
Novel Foods Approval from EFSA Sabinsa President of European Operations, Dr. Umar
Jan gave informartion about approval from EFSA. Dr. Umar Jan told “The approval confirms that our product fulfils all safety requirements.
It is approved for use as a food supplement for adults, with an upper limit on dosage of 140mg per day. It is thanks to the solid science behind C3 Reduct, of course, that we
have the Novel Foods approval from EFSA.
In terms of outcomes, targeted research has shown that C3 Reduct can support the health of organs such as the liver, the lungs, the gut – and even the brain.
To pick out just some examples, addressing gut health, our curcuminoid has been shown to attenuate inflammatory responses and maintain overall colon health, resulting in reduced formation of colon polyps.
Its anti-inflammatory benefits were again evident from studies carried out in the area of liver health. These demonstrate that C3 Reduct has a protective effect against oxidative stress and the damage to this organ that can result.
In the case of the brain, the antioxidant and anti-inflammatory function of Sabinsa’s
tetrahydrocurcuminoids has been verified in relation to reductions in glutathione, helping to reduce, in turn, neurodegeneration.
For the lungs, our product has a demonstrably beneficial impact in helping to mitigate fibrosis, according to unpublished trials, reducing the incidence of key inflammatory markers.” Dr. Umar Jan concluded his speech as “Other results of interest include those from trials showing that C3 Reduct can reduce blood glucose, findings which suggest a beneficial role for Sabinsa’s product in managing healthy sugar levels.
Last but not least, we should mention the benefits of our curcuminoid in sports nutrition. Once again, it is the well-documented anti-inflammatory properties of the ingredient
which offer great promise. Curcumin C3 Reduct is shown to activate 250 times the amount of Adenosine Monophosphate Protein Kinase (AMPK).
By the way, AMPK is the central regulator of energy homeostasis, balances the supply of nutrients with energy demand, and stimulates ATP production under energy- depleted conditions.
By activating AMPK, C3 Reduct helps to reduce excess glucose and fats, burning them for energy. All in all, Sabinsa’s C3 Reduct delivers a wide array of opportunities for formulators and NPD professionals.”
